Qualigen Therapeutics Enhances Executive Team And Board Expertise With Key Appointments, New Auditor Engagement, And Governance Enhancements For Long-Term Growth

Qualigen Therapeutics, Inc. announced a series of significant leadership and governance changes designed to strengthen its executive team, enhance financial transparency, and support the company’s next phase of strategic growth. Effective October 2, 2025, Jerry (Jiawei) Wang was appointed as Co-Chief Executive Officer, and Koti Meka was appointed as Chief Financial Officer of Qualigen Therapeutics. Mr. Wang, a founding member of Faraday Future, has been deeply involved in the company’s strategic development since 2014, including raising over $3 billion in funding and leading the successful initial public offering in 2021. 

Mr. Meka, previously the CFO of Faraday Future, has extensive experience in finance, having worked at Ford Motor Company from 2002 to 2016 in areas including cost optimization, product development finance, and corporate finance. These appointments reflect Qualigen’s focus on building a globally oriented management team with strong operational and financial expertise. In connection with the company’s recently closed private placement on September 29, 2025, Qualigen’s Board of Directors expanded with the addition of three new members: Kevin Chen, appointed as an Independent Director on September 26, 2025; Chad Chen; and Jay Sheng. 

Jay Sheng was named Chairman of the Audit Committee, with Graydon Bensler and Chad Chen also joining the committee. Additionally, Chad Chen, Kevin Chen, and Jay Sheng were appointed members of both the Nominating & Corporate Governance Committee and the Compensation Committee. Jay Sheng currently serves on the board of Faraday Future and as Head of Operations & Finance Director at FF Global Partners LLC, a role he has held since June 2022. Previously, he was Deputy Managing Director of China Aviation Fuel (Europe) Limited, a subsidiary of China Aviation Oil (Singapore) Corporation. 

Kevin Chen is Chief Economist and Chief Investment Officer at Horizon Financial and holds board positions at several publicly listed companies, including CurrenC Group, Australian Oilseeds Investments, and Scage Future on Nasdaq, as well as Capitan Investment Ltd. on the Toronto Stock Exchange. He also serves as an adjunct associate professor at New York University and has lectured at Harvard University, Fordham University, Pace University, and IESE Business School. 

Chad Chen is a board member of Faraday Future and a partner at Yoka | Smith, LLP, representing clients in both litigation and non-litigation matters, including corporate disputes, product liability defense, class action defense, and business transactions, as well as serving as outside counsel for governmental agencies. Prior to joining Yoka | Smith worked in-house at an alternative energy company. In connection with the same offering, Cody Price and Robert Lim resigned from the Board, and Campbell Becher resigned as Director while continuing as President of the company. All resignations were amicable and not due to any disagreements with the company’s operations, policies, or practices.

On October 3, 2025, Qualigen’s Audit Committee approved the engagement of Macias Gini & O’Connell LLP (MGO) as the company’s new independent registered public accounting firm to audit the fiscal year ending December 31, 2025, and to perform interim reviews for the 2025–2026 financial reporting periods, subject to completion of client acceptance procedures. MGO also serves as the auditor for Faraday Future. Previously, on October 1, 2025, WhitumSmith+Brown, PC (Withum) resigned as Qualigen’s independent registered public accounting firm, with the resignation not resulting from any disagreement with the company.

Kevin Richardson, Co-CEO of Qualigen Therapeutics, stated that these appointments and governance enhancements represent a significant step forward for the company. He emphasized that with strengthened leadership, new board expertise, and a renewed commitment to transparency and compliance, Qualigen is well positioned to execute its long-term growth strategy and deliver lasting shareholder value.